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Abstract 
 
Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM). JNK 
signaling has been implicated in MM pathogenesis, but its function is unclear. To elucidate the 
role of JNK in MM, we evaluated the specific functions of the two major JNK proteins, JNK1 
and JNK2. We show here that JNK2 is constitutively activated in a panel of MM cell lines and 
primary tumors. Using loss-of-function studies, we demonstrate that JNK2 is required for the 
survival of myeloma cells and constitutively suppresses JNK1-mediated apoptosis by affecting 
expression of poly(ADP-ribose) polymerase (PARP)14, a key regulator of B-cell survival. 
Strikingly, we found that PARP14 is highly expressed in myeloma plasma cells and associated 
with disease progression and poor survival. Overexpression of PARP14 completely rescued 
myeloma cells from apoptosis induced by JNK2 knockdown, indicating that PARP14 is 
critically involved in JNK2-dependent survival. Mechanistically, PARP14 was found to promote 
the survival of myeloma cells by binding and inhibiting JNK1. Moreover, inhibition of PARP14 
enhances the sensitization of MM cells to anti-myeloma agents. Our findings reveal a novel 
regulatory pathway in myeloma cells through which JNK2 signals cell survival via PARP14, 
and identify PARP14 as a potential therapeutic target in myeloma. 
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Introduction 
 
Multiple myeloma (MM) is a neoplasm of terminally differentiated B cells, characterized by 
accumulation of clonal, long-lived plasma cells in the bone marrow (BM) as well as 
extramedullary sites.1 Despite the significant progress that has been made in the identification 
of deregulated pathways, MM remains incurable. Further understanding of the biology of this 
disease is therefore needed in order to develop more effective therapies.2,3 
 
Notable characteristics of myeloma cells include a low proliferative capacity and a weak 
apoptotic index in vivo.1,2 Thus, pro-survival mechanisms play central roles in the 
accumulation of the malignant clone in MM.2,4,5 Among the signaling pathways involved in the 
regulation of cell survival are members of the mitogen-activated protein  kinase (MAPK) 
family, which includes three members: extracellular-regulated kinase (ERK1/2), Jun N-terminal 
kinase (JNK) and p38-MAPK signaling.6-8 While the functions of ERK1/2 and p38-MAPK in 
MM have been defined in recent studies,9,10  the role of JNK in the pathogenesis of the 
disease is unclear. 
 
Signaling via JNK plays key roles in induction of apoptosis, cell proliferation, transformation 
and survival through the phosphorylation and regulation of its substrates.11 As these cellular 
responses are important in tumorigenesis, JNK signaling has been implicated in human 
cancers.11,12 Two major JNK proteins, JNK1 and JNK2, are expressed ubiquitously and each 
has two different splicing isoforms (p46 and p54).11 Although JNK1 and JNK2 have been 
considered redundant kinases, there is evidence for distinct or even opposing functions of 
JNK1 and JNK2 in tumorigenesis.12-15 Thus, it has been reported that JNK2, but not JNK1, is 
essential for growth of various human cancer cells including lung,16,17 glioblastoma,18,19 
prostate and skin.20-22 In contrast, a recent study reported that JNK1 is essential for liver 
carcinogenesis, while JNK2 appears to be dispensable.12,23 Taken together, these data infer a 
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context- and tissue-specific functions for JNK1 and JNK2 in cancer development.12 Although it 
has been suggested that differential regulation of specific cellular targets is the molecular 
basis for the distinct functions of JNK1 and JNK2 in different tumours,12  there is a paucity of 
understanding regarding the identification of targets regulated by the individual JNK members.  
  
A role for JNK signaling in MM has also been reported, although the proposed functions are 
controversial.24-27 Whilst JNK activation was shown to promote cell-cycle progression in MM,24 
JNK activation mediates apoptosis induced by treatment with anti-myeloma agents, often 
through activation of caspases.25-27 Furthermore, inhibition of JNK with the chemical inhibitor, 
SP600125, induces growth arrest in MM cell lines.24 However, the individual contribution of 
JNK1 and JNK2 to the pathogenesis of MM is not known due to the lack of chemical inhibitors 
specific for each JNK protein.28 
 
Here we show that JNK2 is constitutively active in myeloma cells, and inhibits the pro-
apoptotic activity of JNK1 through effects on poly(ADP-ribose) polymerase (PARP)14, thus 
promoting survival in myeloma cells. PARP14, a member of the macro-PARP subfamily of 
PARP proteins, is an ADP ribosyltransferase that transduces survival signals in murine 
primary B cells by regulating expression of B-cell survival factors as well as by repressing an 
apoptotic program involving caspases.29,30 In the mouse, PARP14 has been shown to facilitate 
B-lymphoid oncogenesis driven by oncogenic c-Myc.31 However, the mechanisms underlying 
the survival function of PARP14 have not been previously investigated in MM or other types of 
human cancer. 
We demonstrate that PARP14 acts as a physiological downstream effector of the JNK2-
dependent pro-survival signal by binding to JNK1 and inhibiting its activity. We also find that 
expression of PARP14 correlates with disease progression and poor prognosis in MM.  
Therefore, this study describes a novel regulatory pathway in myeloma cells through which 
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JNK2 promotes survival and suggests that selective inhibition of PARP14 might be of 
therapeutic value. 
 
 
Results 
 
JNK2 is constitutively active in myeloma cells 
Activation of JNK in BM trephine biopsies from four patients with newly diagnosed MM was 
assessed by immunohistochemistry using an antibody that recognizes both phospho-active 
JNK1 and JNK2 (p-JNK). All myeloma cells showed strong nuclear staining for p-JNK in all the 
samples examined. In contrast, no p-JNK staining was detectable in the normal plasma cells 
in tonsillar samples (n=3) (Figure 1A). Consistently, analysis of JNK activation by 
immunoblotting in six additional MM cases showed considerable increase of p-JNK in BM 
plasma cells (selected as CD138+CD38hiCD45low/-)32 in 5 out of 6 cases compared to normal B 
cells (Figure 1B, left). Interestingly, we also observed that intensity of p-JNK2 (p-p54, which is 
the prominent spliced form of JNK2) was significantly higher than p-JNK1 (p-p46, the 
prominent spliced form of JNK1)11 (Figure 1B, right), indicating that JNK2 activity was 
increased in myeloma plasma cells. Increased levels of p-JNK2 were also found in a panel of 
MM cell lines compared to p-JNK1 (Figure 1C). The differences in the levels of p-JNK2 versus 
p-JNK1 in MM cell lines and primary tumors were not due to differential protein expression 
(Figures 1B,C). Further validation was obtained using a JNK2 kinase assay. A dramatically 
elevated JNK2 activity was detected in MM cell lines, whereas normal B cells lacked a 
comparable JNK2 activity (Figure 1C). In contrast, JNK1 kinase assay showed that JNK1 
activity was nearly undetectable in all MM cells tested, and comparable to that found in normal 
B cells (Figure 1C). These data indicate that JNK2 is constitutively activated in myeloma 
plasma cells.  
 
Barbarulo A., et al. 
 
Page 6 of 31 
 
To establish the function of constitutive JNK2 activity in myeloma cells, expression of JNK2 
was knocked down in the human MM cell line, RPMI-8226, using JNK2-specific shRNA 
lentiviruses. We used the pLL3.7 lentiviral vector to expresses JNK2 shRNA (shJNK2) 
together with GFP in a bicistronic fashion.33,34 Lentiviruses expressing JNK1 shRNA (shJNK1) 
or non-specific shRNA (shNS) were used as controls. Knockdown was specific, as shRNAs 
did not affect expression of other related MAPK proteins (ERK1/2 and p38), as verified by 
western blots (WB) (Figure 1D). As shown in Figure 1E, shJNK2 expression caused a 
progressive reduction of the GFP-positive cells over time compared to shJNK1 or shNS, 
despite the three lentiviruses each yielding GFP-positive cells in RPMI-8226 cells with 
comparable efficiency two days after infection (supplemental Figure S1A). This demonstrates 
that cells expressing shJNK2 and GFP were negatively selected from the population due to 
cell death and indicates a role for JNK2 but not JNK1 in RPMI-8226 cell viability. In contrast, 
BJAB cells, which are derived from Burkitt’s lymphoma (BL) tissue, were unaffected by 
infection with shJNK1, shJNK2 or shNS lentiviruses (Figure 1F) despite JNK1 or JNK2 protein 
being effectively knocked down (Figure 1G). These results are consistent with other studies 
demonstrating redundant roles for JNK1 and JNK2 proteins in BLs.14,35 
 
Knockdown of JNK2 induces apoptosis  
To provide further evidence for cell death in shJNK2-infected MM cells, we quantified 
apoptosis measuring the sub-G1 population using propidium iodide (PI) staining as well as 
AnnexinV/7AAD staining and activation of caspases. Flow cytometric (FCM) analysis of PI-
stained RPMI-8226 cells as early as 4 days after infection revealed that JNK2 silencing 
resulted in an approximate 6-fold increase in apoptosis, compared with JNK1 or control 
silencing (Figure 2A; supplemental Figure S1B). The percentage of apoptotic cells in shJNK2-
infected RPMI-8226 cells further increased with time, and by 8 days post-transduction had 
reached 89.8% (Figure 2A; supplemental Figure S1B). We extended these analyses to two 
additional MM cell lines, MM1.S and JJN3. Efficient knockdown of JNK2 correlated with a 
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significant induction of apoptosis (Figures 2A,B; supplemental Figures S1C,D). Depletion of 
JNK2 also resulted in a robust cleavage of procaspase-9, -3 as well as of downstream 
PARP1, and the appearance of active cleavage products of the expected size in each case 
(shJNK2-infected cells). As expected, in BJAB cells JNK2 depletion did not induce apoptosis 
(Figure 2A; supplemental Figure S1F), confirming that JNK2 is not essential for basal survival 
of BJAB cells. In contrast to JNK2 silencing, the silencing of JNK1 did not affect survival in any 
of the cell lines tested (Figures 2A,B). Together, these data indicate that JNK2 is required for 
myeloma cell survival.  
 
JNK2 constitutively inhibits JNK1-dependent apoptosis in MM cells  
As previous studies have shown that JNK2 negatively regulates JNK1 activity and promotes 
survival in colorectal cancer cell lines by constitutively suppressing JNK1-mediated 
apoptosis,36,37 we investigated whether this was the case for MM. In-vitro kinase assays 
revealed that JNK2 knockdown led to a robust increase in JNK1 activity in MM cells compared 
to control shNS-infected cells (Figure 2C, JNK1 K.A.). This effect of JNK2 knockdown was 
specific, as p38 and ERK1/2 phosphorylation was comparable in shNS-, shJNK1-, and 
shJNK2-infected cells (Figure 2C). Notably, JNK2 depletion did not result in a significant 
increase of JNK1 activity in BJAB cells (supplemental Figure S1F, compare lanes NS and 
JNK2). As predicted, in all cell lines tested JNK2 activity was unaffected by JNK1 depletion 
(Figure 2C; supplemental Figure S1F, JNK2 K.A, compare lanes NS and JNK1). The data 
indicate that JNK2 specifically inhibits basal JNK1 activity in MM cells.  
 
Next, we examined whether JNK1 silencing can rescue JNK2-depleted cells from apoptosis. 
As shown in Figures 2D and 2E, apoptosis induced by JNK2 depletion was completely 
reversed by co-silencing JNK1 with JNK2. Remarkably, cleavage of casapse-3 was abolished 
when JNK1 was co-silenced with JNK2 (Figure 2F), indicating that JNK1 is an essential 
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mediator of apoptosis induced by JNK2 depletion. Our data therefore indicate that JNK2 
regulates myeloma cell survival by suppressing basal JNK1-mediated apoptosis.  
 
JNK2 regulates expression of PARP14 in MM cells   
To dissect the mechanism of JNK1 inhibition by JNK2 in myeloma cells, we screened for 
known B-cell survival factors responsive to JNK2 silencing. PARP14 is a well-established pro-
survival protein that has been implicated in protecting B-lymphocytes against apoptosis.30 
PARP14 expression has been also shown to promote B-cell lymphomagenesis through 
supporting cell survival signals in mice.31 These observations led us to investigate whether 
levels of PARP14 were affected by JNK2 depletion. Indeed, PARP14 expression levels were 
markedly reduced in MM cells by knockdown of JNK2 but not JNK1 or control (Figure 3A). The 
reduction in PARP14 levels was specific, as there was no difference between shJNK1-, 
shJNK2-, and shNS-infected cells in terms of PARP9, another macro-PARP family member.38 
This indicates that JNK2 modulates PARP14 expression in myeloma cells (Figure 3A). 
Intriguingly, reduced PARP14 protein levels were not observed in JNK2-silenced BJAB cells, 
suggesting that PARP14 expression is controlled by cancer cell-specific mechanisms (Figure 
3A).  
 
To examine the expression of PARP14 further, BM biopsies from four MM patients were 
examined by immunohistochemistry. Over 80% of the neoplastic cells in all myeloma samples 
tested had high expression of PARP14. Normal control sections (n=3) showed very low 
PARP14 expression in a proportion of plasma cells within the tonsillar tissue. As with p-JNK, 
PARP14 expression was stronger in the nucleus as compared to the cytoplasm (Figure 3B). 
The expression of PARP14 was also confirmed by immunoblotting using MM cell lines and 
plasma cells obtained from the BM aspirates of six additional MM patients.  PARP14 levels 
were increased in MM lines (sensitive to JNK2 depletion) and primary cells compared with 
normal B cells (Figure 3C). In contrast, 2 of 3 JNK2-independent BL cell lines (data not 
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shown), Ca46 and Raji, did not have detectable PARP14 protein (Figure 3B). The third cell 
line, BJAB, had high levels of PARP14 protein (Figure 3B), confirming that JNK2-independent 
mechanisms of regulation exist. To gain additional clinical insights, we examined the 
expression of PARP14 transcripts in MM and BL using publicly available gene-expression 
datasets.39-41 We observed that PARP14 expression significantly increases in MM plasma 
cells compared to monoclonal gammopathy of undetermined significance (MGUS) or normal 
BM plasma cells, indicating a positive correlation between PARP14 expression and disease 
progression (Figure 3D, left). In contrast, no significant differences were observed between 
normal germinal center (GC) B-cells and BL cases (Figure 3D, right). 
 
Knockdown of PARP14 induces apoptosis  
We next asked if PARP14, like JNK2, is required for MM cell survival. As with JNK2, depletion 
of PARP14 by shRNA (shPARP14) induced apoptosis (Figures 4A-C). Silencing was specific, 
as shPARP14 did not affect expression of PARP9 (Figure 4D). The impact of PARP14 
knockdown in two additional MM cell lines, OPM-2 and KMS12BM, was monitored by the 
progressive disappearance of GFP-positive cells in shPARP14-infected cells (Figure 4E). 
Interestingly, PARP14 knockdown markedly increased JNK1 activity with magnitude similar to 
JNK2 knockdown, indicating that PARP14 is required for JNK1 inhibition (Figure 4C, 
supplemental Figure S2A). This effect of PARP14 knockdown was specific, as p38 and 
ERK1/2 phosphorylation/activation was comparable in shNS- and shPARP14-infected cells 
(supplemental Figure S2B). Similarly, JNK1 activation and a dose-dependent apoptosis were 
also induced by the pan-PARP inhibitor PJ-34, which has been previously used to examine 
PARP14 function (supplemental Figure S2C,D).29,30,42 Notably, PARP14 knockdown did not 
affect survival of BJAB cells (Figures 4A,C), despite these cells exhibit high PARP14 protein 
levels (Figure 3C) that were effectively knocked-down (Figure 4D), in accordance with their 
insensitivity to JNK2 depletion (see Figure 1F and 2A). Together, these data indicate that 
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knockdown of PARP14 resembles JNK2 knockdown, and suggest that JNK2 may mediate MM 
cell survival by regulating the levels of PARP14. 
 
PARP14 mediates survival signaling by JNK2  
To test directly the role of PARP14 in JNK2-mediated survival in MM, we examined the effects 
of ectopic expression of PARP14 in JNK2-depleted cells using the lentiviral expression vector, 
pWPI.34 Because the large size of the PARP14 ORF precluded efficient packaging of lentivirus 
particles, we generated PARP14(ΔN553), a truncated form of PARP14 that has previously 
been found to mimic its physiological functions (Figure 5A).29 We tested whether apoptosis 
caused by JNK2 knockdown could be reversed by ectopic expression of PARP14(ΔN553). 
RPMI-8226 cells infected with either PARP14(ΔN553) or empty pWPI lentiviruses were double 
infected with shJNK2 lentivirus. PARP14(ΔN553)-overexpression was confirmed by WB 
(Figure 5B). Of note in PARP14(ΔN553)-overexpressing cells, levels of total PARP14 
(endogenous plus exogenous) were comparable with those in control cells (Figure 5B; 
compare lane 1 with lane 3). As shown in Figure 5C (left panel), apoptosis induced by JNK2 
knockdown was completely reversed by PARP14(ΔN553) overexpression in RPMI-8226 cells. 
Notably, the protective efficacy of PARP14(ΔN553) overexpression against this killing was 
comparable to that of control shNS-infected cells (see Figure 2A), whereas pWPI expression 
afforded no protection to apoptotic shJNK2-infected cells. Similar results were observed in 
additional MM cells (Figure 5C,D and data not shown). Remarkably, ectopic expression of 
PARP14(ΔN553)  suppressed JNK1 activity in JNK2-depleted cells (Figure 5B; JNK1 K.A.). 
These results show that restoration of PARP14 expression rescues the apoptotic phenotype in 
myeloma cells caused by JNK2 depletion.  
 
PARP14 binds and inhibits JNK1 to promote survival  
As a tool to further dissect the mechanism of JNK1 inhibition by JNK2 and PARP14, we co-
expressed FLAG-tagged PARP14 in HEK293T cells with HA-JNK2p54, HA-JNK1p46 or HA-
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empty vector, and investigated protein associations by combined immunoprecipitations and 
WB analyses. PARP14 specifically bound to JNK1p46, but not JNK2p54, and this binding was 
confirmed with PARP14(ΔN553) and PARP14(ΔN1470) (a mutant lacking the three macro 
domains) (Figure 6A; se also Figure 5A), indicating that the C-terminal of PARP14 is involved 
in this interaction. Importantly, an association between endogenous PARP14 and JNK1 was 
confirmed in both RPMI-8226 and BJAB cells. Anti-JNK1 antibodies co-immunoprecipitated 
PARP14 from parental cells, but not from cells depleted of PARP14 (Figure 6B). JNK1 was 
immunoprecipitated at comparable levels in both parental and shPARP14-infected cells 
(Figure 6B; WB: JNK1), and was not co-precipitated by isotype-matched control antibodies 
(data not shown). We conclude that endogenous PARP14 and JNK1 associate under 
physiological conditions.  
To test whether the binding of PARP14 to JNK1 is sufficient to inhibit JNK1, we generated 
recombinant GST-tagged PARP14(ΔN1470) protein for use in JNK1 kinase assay. Neither 
recombinant PARP14(ΔN1470) nor control protein inhibited active JNK1 in vitro (supplemental 
Figures S3A,B), indicating that PARP14/JNK1 binding is not alone sufficient to explain the 
inhibitory effect of PARP14 on JNK1. Moreover, JNK1 still bound to MKK7, an upstream JNK 
activator, in HEK293T cells overexpressing PARP14 (supplemental Figure S3C).43 Together, 
these results suggest that an additional inhibitory mechanism of JNK1 by PARP14 exits, in 
vivo. 
 
We next investigated whether the protective function of PARP14 also depended on inhibition 
of JNK1. As shown in Figure 6C, co-silencing JNK1 with PARP14 completely rescued MM 
cells depleted of PARP14 from apoptosis, indicating that PARP14 suppresses JNK1-mediated 
apoptosis. The protective effect of JNK1 silencing was reminiscent to that seen in JNK2-
depleted cells (Figure 2D-F), indicating that PARP14 and JNK2 have similar effects on JNK1-
mediated apoptosis. Together, these findings identify PARP14 as the mechanistic link by 
which JNK2 suppresses JNK1, thus promoting myeloma cell survival. 
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PARP14 inhibition can potentiate cytotoxicity of anti-myeloma agents 
As the JNK2-PARP14-JNK1 regulatory axis sustains the survival of MM cells, we investigated 
whether inhibition of PARP14 could be used as a therapeutic strategy in MM. First, we 
evaluated whether PARP14 expression had any impact on anti-MM therapy. Interrogation of 
the dataset GSE2658 revealed that high expression of PARP14 transcripts correlated with a 
significantly shorter survival in patients treated with the Total Therapy 3 protocol,39,40 
suggesting that PARP14 may be implicated in treatment outcomes (Figure 7A). Next, we 
assessed the effects of PJ-34 in combination with the anti-myeloma agent dexamethasone on 
MM cells. PJ-34 significantly enhanced cytotoxicity induced by dexamethasone (Figure 7B), 
suggesting an additive effect. To evaluate whether this effect of PJ-34 was attributable to 
PARP14 inhibition, we either silenced or overexpressed PARP14 in MM1.S cells and assayed 
their viability after treatment with dexamethasone. Depletion of PARP14 significantly 
enhanced the sensitization of MM1.S cells to dexamethasone compared with the control cells 
(Figure 7C). Conversely, MM1.S cells overexpressing truncated-PARP14 were resistant to 
dexamethasone-induced apoptosis compared with control vector. Moreover, addition of PJ-34 
overcame this resistance and resulted in cell death (Figure 7D). Finally, PARP14 knockdown 
also sensitized MM1S cells to bortezomib, lenalidomide and, to a lesser extent, thalidomide 
other clinically relevant compounds used for the treatment of MM (Figure 7E,F). 
 
 
Discussion 
 
The identification of pathways that govern survival of myeloma plasma cells is of great interest 
for possible therapeutic applications, as deregulated survival is a key feature of 
myelomagenesis.1,2,4  
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In this study, we show that JNK2 is a master regulator of survival of myeloma cells, and define 
a new regulatory pathway linking JNK2 to JNK1 through regulation of a novel survival factor of 
B-lineage cells, PARP14.30 Moreover, we report for the first time a correlation of PARP14 
expression with tumor survival and progression in MM. 
 
Elevated activity of p-JNK was found in myeloma plasma cells in all the BM trephine biopsies 
of newly diagnosed MM patients tested, but was nearly undetectable in normal plasma cells in 
the tonsillar samples. This basal JNK activity in myeloma plasma cells exhibits exclusive 
nuclear localization, which is consistent with published reports demonstrating the 
accumulation of p-JNK in the nucleus of cancer cells.18,23 Unlike JNK1, JNK2 has 
autophosphorylation activity that leads to its constitutive activation in several tumour cell 
types.16,18,44 Consistent with this, we found that the major JNK protein that is phosphorylated in 
MM cell lines and primary patient-derived cells is JNK2 (predominantly present as p-p54 
isoform), but not JNK1 (predominantly present as p-p46 isoform), despite p46 and p54 JNK 
proteins being expressed at similar levels. Moreover, p-JNK2 levels and JNK2 activities in 
myeloma cells were higher than in normal B cells, whereas JNK1 activities were weak and 
remained unchanged, suggesting a pathogenic role for JNK2 in this disease. 
 
We systematically evaluated the functional significance of constitutive JNK2 activity using 
shRNA interference, and demonstrated that JNK2 is essential for survival of myeloma cells. In 
this system, silencing of JNK2 or JNK1 expression was found to be highly specific, as levels of 
ERK- and p38-MAPK were not affected. The survival function of JNK2 is not shared by JNK1. 
Indeed, while depletion of endogenous JNK2 protein enhanced apoptosis in MM cell lines, 
reduction in the protein levels of JNK1 did not affect the growth rates of these cancerous cells. 
Moreover, constitutive activation of JNK2 negatively regulated activity of JNK1 since increased 
JNK1 activity was observed in JNK2-depleted cells. Oncogenic function of JNK2 on survival 
was depending on JNK1-mediated apoptosis. Our findings demonstrate that co-silencing of 
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JNK1 with JNK2 completely rescued MM cells from apoptosis induced by JNK2 depletion. 
This was further supported by our observations that JNK1 co-silencing inhibited activation of 
effector caspase-3 triggered by silencing of JNK2 in myeloma cell lines. The fact that no 
alteration of phosphorylation of ERK and p38-MAPK was observed in JNK2-depleted cells 
further suggested that JNK1 is the specific MAPK involved in shJNK2 inducing cell apoptosis.  
 
Our results indicate that JNK2 is not a universal oncogene, as knockdown of JNK2 expression 
in the BL cell line BJAB did not alter the basal cell viability. Recent data has implied that 
JNK2-mediated cell survival involves the regulation of selective pro-survival proteins or tumor 
suppressors in specific cellular contexts. JNK2 cooperates with Ras to promote epidermal 
neoplasia,45 phosphorylates oncoproteins such as STAT3 in non-small cell lung carcinoma 
and Akt in glioblastoma,16,18 and contributes to the inhibition of tumour suppressors in breast 
and colon cancer cells.46,47 Interestingly, we found that JNK2 depletion leads to a reduction of 
PARP14 levels in MM cells, but not in BJAB, suggesting that the JNK2-dependent regulation 
of PARP14 is limited to terminally differentiated B-cells. Elevated expression levels of PARP14 
were found in MM cell lines as well as primary CD138+ MM cells and, intriguingly, correlated 
with the nuclear activity of JNK2 in MM primary tumors. PARP14 levels also appear to have 
important clinical implications for patients with MM as PARP14 gene expression increases 
with disease progression from normal BM plasma cells to early (MGUS) and then to active 
stages of MM. Furthermore, knockdown of PARP14 recapitulated knockdown of JNK2 in MM 
cells by mediating apoptosis, consistent with the hypothesis that JNK2 mediates survival by 
regulating PARP14 expression. Complementary experiments further supported this conclusion 
by showing that the increased apoptosis in JNK2-depleted cells was completely suppressed 
by expression of PARP14. Thus, the function of JNK2 to inhibit apoptosis can be replaced by 
PARP14, consistent with the established role of this protein as a protective factor in primary 
murine B-lymphocytes.30 The obvious question that remains to be addressed relates to the 
mechanisms of reduced PARP14 expression caused by JNK2 depletion. JNK proteins 
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regulate the activity of several transcription factors, such as c-Jun and ATF-2, and the stability 
of non-transcription factors, such as Bcl2.11 Therefore, it is possible that JNK2 may indirectly 
regulate PARP14 expression at either transcriptional or posttranscriptional levels. Further 
studies are required to address this question. 
  
What is the molecular mechanism by which JNK2 and PARP14 proteins cooperate in 
regulating MM cell survival? The JNK2-dependent suppression of JNK1 is apparently 
mediated through PARP14, because JNK1 activity is similarly increased in PARP14-depleted 
cells and the suppression of JNK1 was restored by overexpression of PARP14(ΔN553) in cells 
depleted of JNK2. Consistent with this, apoptosis caused by PARP14 knockdown in MM cells 
was completely reversed by JNK1 co-silencing, indicating JNK1 as a direct mediator of 
apoptosis triggered by PARP14 knockdown. 
 
Along with the three tandem “macro” domains, PARP14 contains a WWE domain and a 
catalytic PARP domain at the C-terminal.38,48 The WWE domain is predicted to mediate 
protein-protein interactions in ubiquitination and ADP-ribose conjugation systems.49 Indeed, it 
has been shown that PARP14 associates with Stat6 and phosphoglucose isomerase through 
its C-terminus.29,49 Furthermore, PARP14 activity was shown to be essential in mediating IL-4-
induced protection of murine B-lymphocytes against apoptosis.30 Although we have not 
addressed whether the enzymatic activity of PARP14 is strictly required for the inactivation of 
JNK1 kinase, we found that PARP14 specifically interacts with JNK1 through its C-terminal 
portion and that overexpression of the latter completely suppressed JNK1 activity. We also 
found that blocking PARP activity using PJ-34 resulted in JNK1 activation and apoptosis. 
Accordingly, neither PARP14/JNK1 interaction was alone sufficient for JNK1 suppression nor 
prevented JNK1 from binding to MKK7, an upstream JNK1 activator. Therefore, it is possible 
that the PARP14 catalytic activity might be involved in JNK1 inactivation. Studies to define the 
role of the PARP14 activity in inhibiting JNK1 kinase activity in more detail are under way. 
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Finally, we observed that high PARP14 mRNA expression correlated with poor survival 
outcomes in newly diagnosed MM patients treated with total therapy 3 protocol.39,40 In line with 
these clinical observations, we showed that inhibition of PARP14 can cooperate with anti-
myeloma agents in inducing more effective cell death, suggesting that PARP14 could be 
targeted to improve anti-MM therapies. Therefore, it will be of interest to examine the role of 
PARP14 in development of drug resistance.  
 
In summary, we identify a novel pathway whereby constitutively active JNK2 promotes 
survival via PARP14, which in turn associates with JNK1 and inhibits its kinase activity; this 
inhibition is crucial for the suppression of basal apoptosis in myeloma cells (Figure 7G). Our 
findings define for the first time the individual role of JNK1 and JNK2 in MM and demonstrate 
that PARP14 is a novel physiological downstream effector of JNK2, thus expanding the 
number of specific targets downstream of JNK2. These results may open new avenues for 
therapeutic intervention in MM. 
 
 
Material and Methods 
 
Patient samples 
After approval from the Hammersmith Hospitals NHS Trust Research Ethics Committee and 
informed consent according to the Declaration of Helsinki, BM samples were obtained from 
patients with MM undergoing routine diagnostic procedure. 
Mononuclear cells were isolated from BM aspirates by Ficoll gradient centrifugation, and 
primary CD138+ MM cells were positively sorted using CD138-conjugated magnetic beads 
(Miltenyi-Biotec, Surrey, UK) as previously reported.32  
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Cells and reagents 
Human MM cell lines (RPMI-8226, JJN-3, MM1.S, OPM-2, KMS12-BM, KMS11 and U266) 
and Burkitt’s lymphoma lines (BJAB, Ca46, and Raji) were cultured in RPMI1640 (Invitrogen, 
Paisley, UK) supplemented with 10% fetal bovine serum (Sigma, Gillingham-Dorset, UK), 100 
U/mL penicillin, 100mg/mL streptomycin, and 2mM L-glutamine (Invitrogen) in a 5%CO2 
incubator at 37°C.32,51 D-MEM (Invitrogen) was used as culture medium to grow human 
HEK293T cells. Normal B cells were isolated from peripheral blood of healthy donors using 
the B-cell isolation kit II (Miltenyi-Biotec), according to the manufacturer’s instructions. 
Dexamethasone and PJ-34 were obtained from Sigma. Bortezomib was obtained from the 
pharmacy of Hammersmith Hospital. Thalidomide and Lenalidomide were obtained from 
Tocris Bioscience (Bristol, UK) and Selleck Chemicals (Huston, USA) respectively. 
 
Plasmids, co-transfection, protein purification, lentiviral preparations and infections 
pcDNA-FLAG, pSRα-HA-JNK1, pcDNA-HA-JNK2 were used previously.52 pcDNA-FLAG-
PARP14 was obtained by sub-cloning the full-length human cDNA of PARP14 (provided by Dr 
Michael Johns) between the KpnI-XhoI restriction site of pcDNA-FLAG. pcDNA-FLAG-
PARP14(ΔN553) and pcDNA-FLAG-PARP14(ΔN1470), encoding amino acids 553-1801 and 
1470-1801 of human PARP14, respectively, were obtained by linearizing pcDNA-PARP14(FL) 
with appropriate restriction enzymes and replacing original fragments with oligonucleotide 
linkers. For co-immunoprecipitations, HEK293T cells were co-transfected using the calcium 
phosphate method with HA-tagged and FLAG-tagged plasmids, as described before.52  
 
To generate pGEX-PARP14(ΔN1470), the cDNA PmeI-PstI fragment of pcDNA-FLAG-
PARP14(ΔN1470) was insert into the BamHI-SmaI sites of pGEX1 along with an appropriate 
oligonucleotide linker. GST-PARP14(ΔN1470) were expressed in E.coli and purified as 
previously described.52 
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Oligonucleotides to obtain shRNA constructs were cloned into the lentiviral vector, pLL3.7, 
using the HpaI-XhoI restriction sites.33,34 Oligonucleotides used are listed in Supplemental 
Table S1. Non-specific shRNA (shNS) was previously described.33 We also used a lentiviral 
vector pWPI for complementary experiments.34 The expression constructs pWPI-FLAG-
PARP14, pWPI-FLAG-PARP14(ΔN553) and pWPI-HA-JNK2 were generated by subcloning 
the full-length PARP14, PARP14(ΔN553) or JNK2 cDNA sequences into the PmeI restriction 
site of pWPI. All constructs were confirmed by nucleotide sequencing. Lentiviral preparations 
were obtained, as previously described.33 Supernatants were harvested, concentrated and 
then used to infect MM cell lines in presence of 8µg/ml polybrene (Sigma) 
 
Apoptosis and cell viability assays 
Apoptosis was assessed by FCM analysis using PI nuclear staining, as previously 
described,33,51 and Annexin-V-eFluor450 and 7-amino-actinomycin D (7AAD) (eBioscience, 
Hatfield, UK) staining, according to the manufacturer’s instructions. The percentage of 
apoptotic cells was calculated on the total population, gating out the cellular fragments using 
the FSC/SSC parameter. Cell viability was assessed using MTT reagent according to the 
manufacturer’s protocol (Sigma). Proportion of live GFP+ was evaluated over time by FCM 
analysis, and expressed relative to the proportion at 2 or 4 days after lentiviral infection. 
 
Western blot, kinase assay, co-immunoprecipitation and antibodies. 
WB, co-immunoprecipitation, JNK1 and JNK2 kinase assays (K.A.) were performed as 
described previously.33,51,53 Antibodies used in these protocols included JNK1 and JNK1/2 (BD 
Biosciences, Heidelberg, Germany); caspase-3, caspase-9, phospho-JNK, phospho-p38, 
phospho-ERK1/2, JNK2, p38, ERK1/2 (Cell Signaling, Danvers, MA, USA); anti-HA-probe, 
PARP9, β-actin (Santa Cruz, Heidelberg, Germany); PARP1 (Calbiochem, Lutterworth, UK); 
PARP14 and anti-FLAG-probe (Sigma).  
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Immunohistochemistry 
Sample preparation was performed as previously described.54 Rabbit anti-human PARP14 
and phospho-JNK were used in a dilution of 1:50. The staining in the myeloma samples was 
reviewed and scored by a qualified hematopathologist (K.N.) in a blinded fashion. Stained 
sections were analyzed with a light microscope (BX51, Olympus) carrying a DP70 digital 
camera.  
  
Gene-expression profiling 
Publicly available gene-expression data for a series of MM (GSE2658 and GSE5900) and 
Burkitt’s lymphoma (GSE12453) primary samples profiled on Affymetrix U133 (Affymetrix, 
Santa Clara, CA, USA) platforms were downloaded and analyzed against human PARP14 
(probe 224701_at).39-41 
 
Statistical analysis 
Data are shown as mean ± SD of three experiments. Statistical significances of differences 
were determined using appropriate tests as described in figure legends. The minimal level of 
significance was P<0.05.  
 
Conflict of Interest 
The authors declare no conflicts of interest. 
 
 
Acknowledgement 
We are grateful to S. Chokshi, R. Williams and J. Dyson for critical comments on the 
manuscript. We also thank D. Trono (Ecole Polytechnique Fédérale de Lausanne, 
Switzerland) for the pWPI lentiviral vector and M. Johns (Imperial College) for the human 
PARP14 cDNA; H. Cooksley, A. Riva (Institute of Hepatology), and P.M. Choy, M.H. Lam and 
Barbarulo A., et al. 
 
Page 20 of 31 
 
V. Patel (MSc students) for technical support. G.F. receives funding from NIH grants R01 
CA084040 and R01 CA098583 and Cancer Research UK grant C26587/A8839. D.O.H. 
receives professorial support from the British Heart Foundation. This study was primarily 
supported by a research grant from Kay Kendall Leukemia Fund (KKL443) to C.B., and in part 
by grants from Italian Association for Cancer Research (Start-up 8557) and the Foundation for 
Liver Research to S.P. 
 
 
References 
 
1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011; 6: 249-
274. 
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. 
Lancet. 2009; 374: 324-339. 
3. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491. 
4. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a 
multistep transformation process. Blood 1998; 91: 3-21. 
5. Witzig TE, Timm M, Larson D, Therneau T, Greipp PR. Measurement of apoptosis and 
proliferation of bone marrow plasma cells in patients with plasma cell proliferative 
disorders. Br J Haematol 1999; 104: 131-137. 
6. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 
2003; 101: 4667-4679. 
7. Geest CR, Coffer PJ. MAPK signaling pathways in the regulation of hematopoiesis. J 
Leukoc Biol 2009;86:237-250. 
8. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. 
Oncogene 2007; 26: 3100-3112. 
Barbarulo A., et al. 
 
Page 21 of 31 
 
9. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, et al. Blockade of the MEK/ERK 
signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic 
anti-myeloma activity in vitro and in vivo. Br J Haematol 2010; 149: 537-549. 
10. Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, et al. 
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. 
Blood 2003; 101: 703-705. 
11. Bogoyevitch MA, Kobe B. Uses for JNK: the many and varied substrates of the c-Jun N-
terminal kinases. Microbiol Mol Biol Rev 2006; 70: 1061-1095. 
12. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer 
development. Nat Rev Cancer 2009; 9: 537-549. 
13. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF. Defective 
neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and 
JNK2. Mech Dev 1999; 89: 115-124. 
14. Anbalagan M, Sabapathy K. JNK1 and JNK2 play redundant functions in Myc-induced B 
cell lymphoma formation. Int J Cancer 2012; 130: 1967-1969.  
15. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003; 2: 199-201. 
16. Nitta RT, Del Vecchio CA, Chu AH, Mitra SS, Godwin AK, Wong AJ. The role of the c-
Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis. 
Oncogene 2011; 30: 234-244. 
17. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. The Jun kinase 2 isoform 
is preferentially required for epidermal growth factor-induced transformation of human 
A549 lung carcinoma cells. Mol Cell Biol. 1999; 19: 1938-1949. 
18. Cui J, Han SY, Wang C, Su W, Harshyne L, Holgado-Madruga M, Wong AJ. c-Jun 
NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma cells. 
Cancer Res. 2006; 66: 10024-10031. 
19. Yoon CH, Kim MJ, Kim RK, Lim EJ, Choi KS, An S, et al. c-Jun N-terminal kinase has a 
pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like 
Barbarulo A., et al. 
 
Page 22 of 31 
 
cells. Oncogene 2012; e-pub ahead of print 16 January 2008; doi: 
10.1038/onc.2011.634. 
20. Yang YM, Bost F, Charbono W, Dean N, McKay R, Rhim JS, Depatie C, Mercola D. c-
Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate 
carcinoma. Clin Cancer Res 2003; 9: 391-401. 
21. Ke H, Harris R, Coloff JL, Jin JY, Leshin B, Miliani de Marval P, Tao S, Rathmell JC, Hall 
RP, Zhang JY. The c-Jun NH2-terminal kinase 2 plays a dominant role in human 
epidermal neoplasia. Cancer Res 2010; 70: 3080-3088. 
22. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L, Flavell RA, Dong Z. 
Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. 
Cancer Res 2001; 61: 3908-3912. 
23. Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells 
and chemically induced mouse liver cancers requires JNK1-dependent p21 
downregulation. J Clin Invest 2008; 118: 3943-3953. 
24. Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, Anderson K. Biologic 
sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. 
Oncogene. 2003; 22: 8797-8801. 
25. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, et al. 
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. 
Blood 2003; 101: 1530-1534. 
26. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Sustained activation of c-jun-
N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple 
myeloma cell lines. Cancer Sci 2006; 97: 540-545. 
27. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, et al. JNK-dependent 
release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. 
J Biol Chem 2003; 278: 17593-17596. 
Barbarulo A., et al. 
 
Page 23 of 31 
 
28. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. c-Jun N-terminal kinase (JNK) 
signaling: recent advances and challenges. Biochim Biophys Acta 2010; 1804: 463-475. 
29. Goenka S, Boothby M. Selective potentiation of Stat-dependent gene expression by 
collaborator of Stat6 (CoaSt6), a transcriptional cofactor. Proc Natl Acad Sci USA 2006; 
103: 4210-4215. 
30. Cho SH, Goenka S, Henttinen T, Gudapati P, Reinikainen A, Eischen CM, et al. PARP-
14, a member of the B aggressive lymphoma family, transduces survival signals in 
primary B cells. Blood 2009; 113: 2416-2425. 
31. Cho SH, Ahn AK, Bhargava P, Lee CH, Eischen CM, McGuinness O, et al. Glycolytic 
rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B 
aggressive lymphoma (BAL) family. Proc Natl Acad Sci USA 2011; 108: 15972-15977. 
32. Spanoudakis E, Hu M, Naresh K, Terpos E, Melo V, Reid A, Kotsianidis I, Abdalla S, 
Rahemtulla A, Karadimitris A. Regulation of multiple myeloma survival and progression 
by CD1d. Blood 2009; 113: 2498-2507. 
33. Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C, et al. Upregulation of 
Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell 
Biol 2007; 27: 3920-3935. 
34. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-
mediated drug-inducible RNA interference. J Virol 2003; 77: 8957-8961. 
35. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. c-Jun N-
terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. 
Blood. 2005;106:1382-1391.  
36. Liu J, Minemoto Y, Lin A. c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is 
essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis. 
Mol Cell Biol. 2004;24:10844-10856. 
37. Ahmed SU, Milner J. Basal cancer cell survival involves JNK2 suppression of a novel 
JNK1/c-Jun/Bcl-3 apoptotic network. PLoS One 2009; 4: e7305. 
Barbarulo A., et al. 
 
Page 24 of 31 
 
38. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an 
old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-528. 
39. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular 
classification of multiple myeloma. Blood 2006; 108: 2020-2028. 
40. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-
expression signature of benign monoclonal gammopathy evident in multiple myeloma is 
linked to good prognosis. Blood 2007; 109: 1692-1700. 
41. Brune V, Tiacci E, Pfeil I, Döring C, Eckerle S, van Noesel CJ, et al. Origin and 
pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by 
global gene expression analysis. J Exp Med 2008; 205: 2251-2268.  
42. Gangopadhyay NN, Luketich JD, Opest A, Visus C, Meyer EM, Landreneau R, et al. 
Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell 
lines. Cancer Invest 2011; 29: 608-616. 
43. Bardwell AJ, Frankson E, Bardwell L. Selectivity of docking sites in MAPK kinases. J Biol 
Chem 2009; 284:13165-13173.. 
44. Cui J, Holgado-Madruga M, Su W, Tsuiki H, Wedegaertner P, Wong AJ. Identification of 
a specific domain responsible for JNK2alpha2 autophosphorylation. J Biol Chem 2005; 
280: 9913-9920. 
45. Ke H, Harris R, Coloff JL, Jin JY, Leshin B, Miliani de Marval P, et al. The c-Jun NH2-
terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res 
2010; 70: 3080-3088. 
46. Ford J, Ahmed S, Allison S, Jiang M, Milner J. JNK2-dependent regulation of SIRT1 
protein stability. Cell Cycle 2008; 7: 3091-3097. 
47. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. Inhibition of 
SIRT1 reactivates silenced cancer genes without loss of promoter DNA 
hypermethylation. PLoS Genet 2006; 2: e40. 
Barbarulo A., et al. 
 
Page 25 of 31 
 
48. Goenka S, Cho SH, Boothby M. Collaborator of Stat6 (CoaSt6)-associated poly(ADP-
ribose) polymerase activity modulates Stat6-dependent gene transcription. J Biol Chem 
2007; 282: 18732-18739. 
49. Aravind L. The WWE domain: a common interaction module in protein ubiquitination and 
ADP ribosylation. Trends Biochem Sci 2001; 26: 273-275. 
50. Yanagawa T, Funasaka T, Tsutsumi S, Hu H, Watanabe H, Raz A. Regulation of 
phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) 
polymerase family-14. Cancer Res 2007; 67: 8682-8689. 
51. Zazzeroni F, Papa S, Algeciras-Schimnich A, Alvarez K, Melis T, Bubici C, et al. 
Gadd45beta mediates the protective effects of CD40 costimulation against Fas-induced 
apoptosis. Blood 2003; 102: 3270-3279. 
52. Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, Matsuda S, et al. Gadd45beta 
mediates the NF-kappaB suppression of JNK signalling by targeting MKK7/JNKK2. Nat 
Cell Biol 2004; 6: 146-153. 
53. Blonska M, Pappu BP, Matsumoto R, Li H, Su B, Wang D, Lin X. The CARMA1-Bcl10 
signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling 
pathway. Immunity 2007; 26: 55-66. 
54. Naresh KN, Lampert I, Hasserjian R, Lykidis D, Elderfield K, Horncastle D, et al. Optimal 
processing of bone marrow trephine biopsy: the Hammersmith Protocol. J Clin Pathol 
2006; 59: 903-911. 
 
 
Figure Legends 
 
Figure 1. JNK2 is constitutively activated in MM primary tumors and cell lines and 
targeting JNK2 results in MM cell death (A) Immunohistochemical analysis of phospho-JNK 
(p-JNK) expression in BM biopsies of newly diagnosed MM patients (Pt=4) and normal 
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tonsillar samples (n=3). Representative sections are shown. Positive staining for p-JNK is 
demonstrated in myeloma plasma cells (white arrowheads) by brown nuclear signal. Positivity 
for p-JNK is completely absent in normal plasma cells (black arrowheads) in the tonsillar 
sample. Images are showing x600 magnification. (B) Western blots (left) with antibodies 
against phosphorylated or total JNK1 and JNK2 showing increased expression of p-JNK in 
CD138-purified myeloma from 6 additional newly diagnosed patients with MM (Pt. 5-10) 
compared with normal B cells isolated from human PBMCs of three healthy donors. Right, 
densitometry analysis of p-p54 and p-p46 bands versus total JNK2p54 and JNK1p46, 
respectively. Intensity of p-p54 (p-JNK2) is significantly higher than p-p46 (p-JNK1). The two-
tailed Wilcoxon signed-rank test was used to compare expression of p-p54 and p-p46 in 
CD138-purified myeloma cells from MM patients. Each symbol represents an individual 
patient; horizontal lines indicate the median. (C) Western blots showing increased expression 
of p-JNK in a collection of human MM cell lines compared with normal B cells, and increased 
levels of p-p54 (p-JNK2) compared to p-p46 (p-JNK1). In vitro kinase assays (K.A.) with GST-
c-Jun as substrate showing JNK1 and JNK2 activities in indicated MM cell lines and normal B 
cells. Total JNK1 and JNK2, and β-actin were used as loading control. (D) Western blots with 
antibodies against both spliced variants of JNK1 (JNK1p46, JNK1p54) and JNK2 (JNK2p46 
and JNK2p54) showing the knockdown of either JNK1 or JNK2 proteins in RPMI-8226 cells 
infected with lentiviruses expressing JNK1, JNK2, but not control (lane NS), shRNA. Total 
p38, ERK1/2 and β-actin were used as loading control. (E, F) Analysis of GFP expression in 
RPMI-8226 MM and BJAB Burkitt’s lymphoma cells infected as in (D) showing a reduction of 
GFP-positive cells over time in RPMI-8226 shJNK2 cells, but not in shJNK1, control or BJAB 
cells. Proportion of GFP-positive cells were assessed at indicated times and expressed 
relative to the proportion on day 2 after infection. Values are the mean ± SD of three 
independent cultures. (G) JNK1 and JNK2 levels were assessed by Western blot in BJAB 
cells infected as in (F).  
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Figure 2. JNK2 promotes MM cell survival by suppressing JNK1-mediated apoptosis. 
(A) RPMI-8226 and MM1.S MM cell lines and BJAB cells were infected with lentiviruses 
expressing JNK1, JNK2 or control non-specific (NS) shRNA, and after the times indicated, 
stained with propidium iodide and analyzed by FCM. Shown is the percentage of apoptotic 
cells in the population (sub-G1 DNA content). Values are the means ± SD of three 
independent experiments. (B) Human myeloma JJN3 cells were infected as described in (A), 
and six days after infection the percentage of AnnexinV+ cells showing either 
AnnexinV+/7AAD- (early apoptosis) and AnnexinV+/7AAD+ (late apoptosis) was assayed by 
FCM using AnnexinV/7AAD staining. Data are expressed as mean ± SD of three separate 
experiments. (C) Western blots, in-vitro JNK1 and JNK2 kinase assay (K.A) of lysates from 
RPMI-8226 and JJN3 cells infected as in (A) for 8 or 10 days, respectively, showing cleavage 
of caspases and PARP1 as well as activation of JNK1 and JNK2 using the indicated 
antibodies and GST-c-Jun as substrate, respectively. Closed and open arrowheads indicate 
the pro-cleaved and cleaved (active) products of the indicated proteins, respectively. 
Activation of p38 and ERK1/2 were analyzed by immunoblotting with the indicated phospho-
specific (p) antibodies. β-actin was used as loading control. (D-E) Co-silencing of JNK1 and 
JNK2 rescues MM cells from apoptosis induced by JNK2 depletion. RPMI-8226, MM1.S and 
JJN3 cells were infected with lentiviruses expressing JNK2 shRNA or JNK1/JNK2 shRNA (ie 
silencing simultaneously both proteins), and the percentage of sub-G1 population and 
AnnexinV+ cells were determined by FCM at day 6, 10 or 8 of infection. (F) Western blots of 
extracts from MM cells used in (D-E) showing levels of cleaved-active caspase-3 (Cl. 
caspase-3), and total JNK1/JNK2. β-actin was used as loading control. Representative results 
from at least three experiments are shown. 
 
Figure 3. PARP14 is overexpressed in MM cells, and its expression correlates with 
disease progression and depends on JNK2. (A) Western blots showing a reduction of 
PARP14 levels in MM cells (RPMI-8226, MM1.S and JJN3) but not in BJAB cells infected with 
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lentiviruses expressing JNK2 shRNA compared to JNK1 shRNA or control NS shRNA. PARP9 
and β-actin levels were analyzed with appropriate antibodies as controls. (B) 
Immunohistochemical analysis of PARP14 expression in BM biopsies of newly diagnosed MM 
patients (Pt=4) and normal tonsillar samples (n=3). Representative sections are shown. 
Positive staining for PARP14 is demonstrated in myeloma plasma cells (white arrowheads) by 
brown nuclear signal. Positivity for PARP14 is completely absent in plasma cells (black 
arrowheads) in the tonsillar sample. Images are showing x600 magnification. (C) Western 
blots showing PARP14 expression in CD138+-selected cells from the BM aspirates of 6 
additional MM patients (Pt. 5-10) and B cells from PBMCs of three healthy donors as well as 
indicated MM and Burkitt’s lymphoma cell lines. β-actin was used as loading control. (D, left) 
Gene-expression analysis of PARP14 from oligonucleotide microarray data GSE2658 and 
GSE5900 (Ref. 39,40) showing significantly higher expression of PARP14 transcripts (log2 
transformed, median-centered values) in MM plasma cells (n=414) compared to normal BM 
(n=22) or monoclonal gammopathy of unknown significance (MGUS) (n=44) plasma cells 
(P<0.0001, nonparametric Kruskal-Wallis one-way analysis of variance; *P<0.05 and 
***P<0.001, Dunn’s multiple comparison post-hoc tests). For each box plot, the whiskers 
represent the 2.5-97.5th percentile range of values, the lower and up boundaries denote the 
25th and the 75th percentile of each dataset, respectively, and the horizontal line represents 
the median value for each group. (D, right) Gene-expression profiling of PARP14 from 
oligonucleotide microarray data GSE12453 (Ref. 41) showing no significant differences of 
PARP14 transcripts levels between normal purified tonsillar germinal center (GC) B cells 
(centrocytes and centroblasts) (n=5) and Burkitt’s lymphoma (BL) cases (n=5) (P=0.1013, 
nonparametric Kruskal-Wallis one-way analysis of variance). The horizontal line indicates the 
mean. 
 
Figure 4. PARP14 expression is required for survival of MM cells. (A) RPMI-8226, MM1.S 
and BJAB cells were infected with lentiviruses expressing PARP14 or control NS shRNA, and 
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after the times indicated, stained with PI and analyzed by FCM. Shown is the percentage of 
apoptotic cells in the population (sub-G1 DNA content). Values are the means ± SD of three 
independent experiments. (B) JJN3 cells were infected as described in (A), and the 
percentage of AnnexinV+ cells showing either AnnexinV+/7AAD- (early apoptosis) and 
AnnexinV+/7AAD+ (late apoptosis) was assayed by FCM using AnnexinV/7AAD staining. 
Data are expressed as mean ± SD of three separate experiments. (C) Western blots and in-
vitro JNK1 kinase assay (K.A) of lysates from RPMI-8226, JJN3 and BJAB cells infected as in 
(A-B) for 10 days, showing cleavage of indicated caspases and PARP1 as well as activation of 
JNK1 using the indicated antibodies and GST-c-Jun as substrate, respectively. Closed and 
open arrowheads indicate the pro-cleaved and cleaved (active) products of the indicated 
proteins, respectively. β-actin was used as loading control (D) Western blots showing the 
knockdown of PARP14 levels in indicated MM cell lines and BJAB cells infected with 
lentiviruses expressing PARP14, but not control (lane NS), shRNA. PARP9 and β-actin were 
used as loading control. (E) Analysis of GFP expression in OPM2 and KMS12-BM infected as 
in (D) showing a depletion of GFP-positive cells over time in shPARP14 cells, but not in 
control cells. Proportion of GFP-positive cells were assessed at indicated times and expressed 
relative to the proportion on day 4 after infection. A representative experiment of three is 
shown.  
 
Figure 5. PARP14 suppresses JNK1-mediated apoptosis in JNK2-depleted cells (A) 
Schematic representation of full-length (FL) (amino-acid residues 1 to 1801) FLAG-tagged 
PARP14 [FLAG-PARP14 (FL)] and the C-terminal fragments of PARP14, FLAG-
PARP14(∆N553) and FLAG-PARP14(∆N1470), used in complementary and co-
immunoprecipitation experiments. The three macro-domains (Macro), the PARP-domain and 
the protein-protein interaction domain WWE are indicated. (B) Representative western blots 
showing ectopic expression of FLAG-PARP14(∆N553) in RPMI-8226 cells infected with 
lentiviruses expressing FLAG-PARP14(∆N553) or empty virus (pWPI), and then double 
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infected with lentiviruses expressing JNK2 shRNA. Endogenous [FL] and exogenous PARP14 
[FLAG-PARP14(∆N553)]  are indicated. Kinase assays (K.A.) showing inhibition of JNK1 
activity in the same RPMI-8226 infected cells. GST-c-Jun was used as substrate. Total 
JNK1/2 and β-actin was used as loading control. (C-D) Ectopically expressed FLAG-
PARP14(∆N553) rescues JNK2-depleted cells from apoptosis. Myeloma cell lines were 
infected as in (B), and apoptosis was assessed by FCM using PI (C) or AnnexinV/7AAD 
staining (D).  Shown are bar graphs representing the mean (± SD) percentage of apoptotic 
cells in the population (sub-G1 DNA content or AnnexinV+ cells) in three independent 
experiments. 
 
Figure 6. PARP14 specifically interacts with JNK1. (A) HEK293T cells were transfected 
with the indicated FLAG-tagged PARP14 and HA-tagged empty vector (HA-vector), HA-JNK1 
or HA-JNK2. After 24 hours, cells were harvested and lysed. Lysates were 
immunoprecipitated (IP) with anti-FLAG and subject to western blots (WB) as indicated. 
Results are representative of three experiments. (B) Western blots with anti-JNK1 
immunoprecipitates (top) or lysates (bottom) from RPMI-8226 (left) and BJAB (right) 
shPARP14 or uninfected (parental) cells, showing association of endogenous PARP14 with 
JNK1. (C) Co-silencing of JNK1 with PARP14 rescues MM cells from apoptosis induced by 
shPARP14. RPMI-8226, MM1.S and JJN3 cells were infected with lentiviruses expressing 
JNK1 or control NS shRNA, double infected with shPARP14, and then the percentage of 
AnnexinV+ cells showing either AnnexinV+/7AAD- (early apoptosis) and AnnexinV+/7AAD+ 
(late apoptosis) was assayed by FCM using AnnexinV/7AAD staining. Values are the mean ± 
SD of three independent experiments. 
 
Figure 7. PARP14 inhibition enhances cytotoxicity of anti-myeloma agents. (A) High 
PARP14 expression significantly correlates with poor survival outcomes post therapy. Shown 
are the Kaplan-Meier overall survival (OS) curves of MM patients treated with total therapy 3 
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(TT3) according to PARP14 expression above or below the median value of 1082 based on a 
dataset GSE2658 (Ref. 39,40) (P= 0.0202). (B) RPMI-8226 and MM1.S viability, as assessed 
by MTT assay, 48 hours after treatment with dexamethasone (Dex) [5µM or 10µM], PJ-34 
[50µM], or both in combination, is shown. Values are the mean ± SD of triplicate cultures. 
**P<0.01 and ***P<0.001, two-tailed t tests. (C) MM1.S were infected with the indicated 
lentiviruses and treated with dexamethasone [10µM]. Cell viability was measured by MTT 
assay at 48 hours after treatment. Values are the mean ± SD of triplicate cultures. **P<0.01 
and ***P<0.001, two-way ANOVA with Bonferroni's post-hoc tests. (D) MM1.S infected with 
lentiviruses expressing FLAG-PARP14(ΔN553) or empty virus (pWPI) were cultured for 48 
hours with dexamethasone [5µM or 10µM] alone or in combination with PJ-34 [50µM]. The bar 
graphs show the percentage of apoptotic cells in the population (sub-G1 DNA content) 
analyzed by FCM. Values are the mean ± SD of triplicate cultures. ***P<0.001, two-way 
ANOVA with Bonferroni's post-hoc tests. (E) MM1.S were infected as in (C) and then treated 
with bortezomib (Bortez) [5nM]. Cell viability was measured by MTT assay at 24 hours after 
treatment. Values are the mean ± SD of triplicate cultures. ***P<0.001, two-way ANOVA with 
Bonferroni's post-hoc tests. (F) MM1.S were infected as in (C) and then treated with 
thalidomide (Thal) [25µg/ml], lenalidomide (Len) [1µM], or left untreated for 72 hours. Cell 
viability was measured by MTT assay. Values are the mean ± SD of triplicate cultures. 
***P<0.001, two-way ANOVA with Bonferroni's post-hoc tests. (H) Schematic model for JNK2-
dependent myeloma cell survival. JNK2 suppresses basal apoptosis in myeloma cells via 
PARP14. Constitutive JNK2 activity regulates levels of PARP14, which in turn inhibits JNK1, 
thereby suppressing the activation of endogenous apoptotic pathways.  
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